The director's selling of ~1.4% of the company's float in two days is the standout signal. While cluster sells are often liquidity-driven, the magnitude here is unusual and not explained by routine 10b5-1 plans (no evidence provided). Monitor for any near-term news (e.g., upcoming data readout, FDA interaction) that could have prompted the sale. If the stock weakens, the selling pressure could accelerate given the prior month's $72M in sales.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 18 $26.00entry
- T+1 · 3mo ago +3.00%α +2.79% · $26.78
- T+5 · 3mo ago +1.31%α +1.51% · $26.34
- T+20 · 2mo ago −33.44%α −31.70% · $17.31
- T+60 · 6d ago −31.08%α −29.04% · $17.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Jason P. Rhodes sold ~$65.2M worth of DYN shares (1.4% of market cap) in a cluster over two days, while CEO John Cox made a minor $131K sale. This is the largest insider sale at Dyne in the current reporting window and occurs against a backdrop of heavy institutional ownership and a bullish analyst consensus. The sheer size and concentration of the sales, particularly the director's, warrant attention despite the academic literature discounting the predictive power of cluster sales.
Key Financial Metrics
Key Facts
- Director Jason P. Rhodes sold ~2.5M shares for ~$65.2M on August 13-14, 2026.
- CEO John Cox sold 4,986 shares for ~$131K on August 13, 2026.
- Total insider sales of ~$65.3M represent ~1.4% of DYN's $4.8B market cap.
- All sales were open-market transactions (code S).
- Prior 30-day insider activity: 9 sells totaling $72.0M.
- Analyst consensus is 90% bullish (19 Buy/7 Strong Buy, 2 Hold).
Financial Impact
~$65.3M in insider selling (1.4% of $4.8B market cap)
Risk Factors
- Potential upcoming negative catalyst (e.g., clinical data miss, regulatory setback) that motivated the large insider sale.
- Further insider selling by remaining large holders if the stock declines.
- High institutional ownership (BlackRock, Fidelity, State Street) could exacerbate sell-off if they reduce positions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-DYN-1787034007865 |
Track record
54 reports on DYN
11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers